Syapse

We’re excited to attend the DIA RWE Conference in Philadelphia and engage in discussions on the evolving role of real-world data (RWD) in oncology regulatory applications!  Syapse has been leading efforts to use RWD to inform regulatory decisions, including our ongoing collaboration with the FDA Oncology Center of Excellence. This partnership focuses on evaluating  RWD study designs and analytic methods, and developing clinically meaningful research questions regarding care, treatment, and outcomes of patients with cancer. Check out some of our early work with the FDA OCE, evaluating  safety and health disparities through the lens of RWD: https://lnkd.in/dstXTvpX Meet our team on-site to explore how Syapse’s expertise in RWE is driving oncology innovation! 🤝 Thomas Brown, M.D., M.B.A. 🤝Harika Sabbineni, B.Pharm. PhD

Syapse is excited to share a new study published in the Journal of Personalized Medicine that highlights the critical link between personalized medicine (PM) integration and improved cancer care outcomes. Using real-world data from the Syapse Learning Health Network, the study revealed a strong correlation between PM adoption and increased use of targeted therapies in metastatic non-small cell lung cancer (mNSCLC) and enhanced clinical trial enrollment in triple-negative breast cancer (TNBC). These findings emphasize the critical role of PM in advancing oncology and offer a roadmap for the future of more effective, data-driven care. Read more: https://lnkd.in/eTiXXEgU. #Oncology #RealWorldData #PersonalizedMedicine #Syapse #CancerCare #ClinicalTrials

We are thrilled to share the publication entitled "Evaluation of real-world tumor response derived from electronic health record data sources: A feasibility analysis in mNSCLC patients treated with chemotherapy”, published in JCO Clinical Cancer Informatics in collaboration with Friends of Cancer Research and other real-world data organizations. Read the manuscript here: bit.ly/3LGcdqS. This publication shares the findings from the latest pilot project in Friends’ Real-World Evidence Portfolio, which establishes methodology for using real-world data (RWD) to evaluate benefit for patients. 💡 The study explored the feasibility of using RWD from EHR to evaluate tumor response in patients with metastatic NSCLC treated with chemotherapy. 💡 Seven RWD partners, including Syapse, each analyzed data from 200 patients. We found that clinician-documented response data was the most available source data across datasets, with variability in the availability of imaging data. The study demonstrated the potential to use clinician-stated response to generate a consistent measure of rw-response across different #RWD sources. 📌 Further standardization and methodological development are needed to support drug effectiveness evaluations using RWD. 📌 The #RWE portfolio generates evidence for best practices for analyzing RWD to help support incorporation of RWE into oncology drug development and regulatory-decision making. Thank you to Thomas Brown, M.D., M.B.A. and Connor Sweetnam for your contributions to this study! #RWEFriends

At Syapse we lead with transparency on how we transform disparate clinical, genomics and outcomes data into a high quality dataset to support patient care, quality improvement and developmental therapeutics. Read about our best-in-industry approach to technology-enabled curation to work collaboratively with cancer registries to achieve more.

We are excited to announce the publication of our latest manuscript in the Journal of Registry Management, titled The Importance of Training and Assessing Quality Control Reviewers in Technology-Enabled Abstraction of Real-World Data: A Case Study. Authored by our dedicated ODS-certified professionals, this study showcases the rigorous processes and validation measures we use to ensure high-quality data. Dive into the publication to discover how we developed a comprehensive Quality Control training program featuring Individual Quality Review (IQR) and Data Point Validation System (DPVS) processes to ensure data quality and Inter-Rater Review (IRR) to evaluate QC reviewers' consistency. Our findings highlight the program's effectiveness and the impressive agreement rates within our cancer data cohorts. Congratulations to Arelis Hernandez, MPH, ODS , Victoria Sweeney, ODS-C, Amelia Deitsch, BS, ODS-C, Katherine L., Lori Boice, Kim Lloyd, RHIT, ODS, Jess Martin AS, HT, ODS-C, Marianna Wicks, MPH, CTR/ODS, and Louise Widmer, for your outstanding work! Explore the manuscript: https://lnkd.in/ep4bvm5Q #RWD #Methodology #OncologyResearch #ODS #QualityControl

On World Lung Cancer Day, we celebrate the resilience and strength of lung cancer survivors and those living with the disease. This year's observance focuses on the power of unity through early screening and the need for increased research funding. At Syapse, we're committed to providing Real-World Data to help lung cancer researchers drive advancements that will improve early detection and develop better treatments. Let's always remember we are stronger together, and continue to push for the research that brings us closer to a cure. Learn More: Take a look at our most recent study, which highlights the real-world impact of comprehensive genomic profiling on biomarker detection, receipt of therapy, and clinical outcomes in advanced Non–Small Cell Lung Cancer. https://lnkd.in/eg8mdzC7 #WorldLungCancerDay #WLCD24 #LungCancerSurvivors #EarlyDetection #ResearchMatters #RWE #RWD #UnitedAgainstLungCancer

Thrilled to share our collaborative study with Illumina, published in the Journal of Clinical Oncology (JCO) Precision Oncology! Using data from the Syapse Learning Health Network, we demonstrated that Comprehensive Genomic Profiling (CGP) significantly improves clinical outcomes for advanced NSCLC patients. This manuscript highlights the transformative potential of CGP in community oncology practices. Congratulations to the incredible teams at Illumina and Syapse for this impactful work!

This year's ASCO meeting underscored what an exciting time this is for advancements in cancer research, and cancer medicine, and the important impact that this work has for patients with cancer. One of the driving themes of this meeting is the rapid evolution of Precision Oncology, with existing targeted therapies moving “up-stream” to early stage disease. This resulting in a direct impact on cure rates, along with an increasing number of biomarkers and associated druggable targets that are rapidly advancing the development of new cancer treatments.  RWD was a continuing topic at ASCO. An ever important tool in advancing therapies is the leveraging of RWD to support patient care, along with supporting regulatory submissions to the FDA. With regard to patient care, RWD can help assess the compliance with rapidly evolving patient care guidelines, showing the adoption rate of newly approved targeted therapies, and the testing rates for their respective companion diagnostics. RWD also allows for post-approval evaluation of safety and efficacy in the broader population, thus helping to address health care disparities, to include assessing the impact of social determinants of health. During this exciting time, we at Syapse continue to be dedicated to our health system and life science partners in lessening the burden of cancer for all populations. 

A huge congratulations to our team for their successful poster presentation at #ASCO2024, on how we can use geospatial techniques to better understand the influence of social determinants of health on stage at diagnosis for breast, bladder, and non-small cell lung cancers. Check out the research here: https://lnkd.in/edPrP7ub

Check out our new research to be presented at #ASCO24! While most researchers are aware that social determinants of health (SDOH) can influence the cancer journey, SDOHs are rarely used in research due to privacy restrictions. We geocoded the data from the Syapse Learning Health Network, and evaluated the influence of five SDOHs on stage at diagnosis in breast, bladder, and non-small cell lung cancers (NSCLC). To learn more about our findings, stop by the poster presentation on Monday, June 3rd from 9-12pm, or visit our booth #15157! For more information on this study, or to schedule a meeting with a member of our team, click the link below: https://lnkd.in/e2DV68Dh